⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Official Title: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

Study ID: NCT05074810

Study Description

Brief Summary: This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.

Detailed Description: This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety and tolerability and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C mutant NSCLC.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Rocky Mountain Cancer Center, LLP, Boulder, Colorado, United States

Georgetown University Medical Center, Washington, District of Columbia, United States

MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,, Washington, District of Columbia, United States

Illinois Cancer Specialists, Arlington Heights, Illinois, United States

Maryland Oncology & Hematology, P.A., Rockville, Maryland, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Henry Ford Health System, Detroit, Michigan, United States

Minnesota Oncology Hematology, P.A, Woodbury, Minnesota, United States

Washington University School of Medicine, Saint Louis, Missouri, United States

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Ohio State University Brain and Spine Hospital, Columbus, Ohio, United States

Consultants in Medical Oncology & Hematology, Broomall, Pennsylvania, United States

Alliance Cancer Specialists,, Horsham, Pennsylvania, United States

Texas Oncology, Austin, Texas, United States

Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, United States

Texas Oncology, Longview, Texas, United States

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States

Virginia Cancer Specialists, PC, Fairfax, Virginia, United States

University Hospital Gent, Gent, , Belgium

CHRU of Lille, Lille, , France

Hôpital Cochin, Paris, , France

Hôpital Foch, Suresnes, , France

Leids Universitair Medisch Centrum, Leiden, , Netherlands

Erasmus MC, Rotterdam, , Netherlands

Hospital Teresa Herrera (C.H.U.A.C), A Coruña, , Spain

Hospital General Universitario Gregorio Marañón, Madrid, , Spain

Hospital Universitario Fundación Jiménez Díaz, Madrid, , Spain

Hospital Universitario Virgen De La Victoria, Málaga, , Spain

Hospital Universitario Virgen de la Macarena, Sevilla, , Spain

University of Leicester, Leicester, , United Kingdom

Royal Marsden Hospital, London, , United Kingdom

Royal Marsden Hospital, Sutton, , United Kingdom

Contact Details

Name: MD Verastem

Affiliation: Verastem, Inc.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: